Paris- February 19 2025- Following completion of the required social and corporate procedures, Sanofi and CD&R announced that they have signed the share purchase agreement with the sale of a 50% controlling stake in Opella to CD&R. Bpifrance is expected to participate as a minority shareholder with a c.2% stake in Opella, with Sanofi remaining a significant shareholder.

Also Read : Solera Health expands leadership team following $40M series E funding

The terms of the transaction remain unchanged from those previously disclosed, and closing is expected to take place in Q2 2025 at the earliest. This transaction remains subject to obtaining customary regulatory approvals from the competent authorities.